Suppr超能文献

使用氟替卡松/沙美特罗联合用药的慢性阻塞性肺疾病患者与单独使用其他吸入性类固醇和支气管扩张剂的患者的生存率比较。

Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.

作者信息

Mapel Douglas W, Nelson Leila S, Lydick Eva, Soriano Joan, Yood Marianne Ulcickas, Davis Kourtney J

机构信息

Lovelace Clinic Foundation, Albuquerque, NM 87106, USA.

出版信息

COPD. 2007 Jun;4(2):127-34. doi: 10.1080/15412550701341111.

Abstract

Recent retrospective studies have suggested that use of inhaled corticosteroids (ICS) may improve survival in chronic obstructive pulmonary disease (COPD), particularly when combined with a long-acting beta-agonist (LABA). However, the study methodologies have been questioned, and no study has examined the survival effect of the newer combination ICS/LABA inhalers. The goal of this project was to further examine the relationship between ICS treatment, with or without LABA, and survival in COPD. COPD patients were identified from the administrative databases of four different integrated health care delivery systems. All patients who were diagnosed with COPD between September 1, 2000 and August 31, 2001 and who had at least 3 months treatment with either a combined fluticasone/salmeterol inhaler (FSI, N=866), any ICS used with a LABA (ICS/LABA, N=525), ICS alone (N=742), LABA alone (N=531), or a short-acting bronchodilator alone (SABD, N=1832), were included. Analyses were conducted using three different analysis approaches that adjust for various biases that may affect the results. In the basic Cox proportional hazards models, use of FSI, ICS/LABA, ICS alone, and LABA alone had significant survival benefits as compared to SABD, after adjustment for differences in age, gender, comorbidities, asthma status, and disease severity (HRs 0.61 [0.45-0.83], 0.59 [0.46-0.77], 0.76 [0.61-0.95], 0.75 [0.57-0.98], respectively). Propensity score matching to reduce the clinical differences between the treatment groups versus the SABD reference group found very similar results. Nested case-control analyses, which are based on survival status instead of treatment, continued to show a significant survival benefit for FSI, ICS/LABA, and ICS alone. Treatment with FSI or another ICS with or without LABA is associated with improved survival in COPD. The treatment benefit is reproducible and is robust to application of a number of different analysis techniques designed to adjust for differences in confounding variables and for bias by indication.

摘要

近期的回顾性研究表明,使用吸入性糖皮质激素(ICS)可能会提高慢性阻塞性肺疾病(COPD)患者的生存率,尤其是与长效β受体激动剂(LABA)联合使用时。然而,这些研究方法受到了质疑,且尚无研究考察新型ICS/LABA联合吸入器的生存效果。本项目的目的是进一步研究使用或不使用LABA的ICS治疗与COPD患者生存率之间的关系。从四个不同的综合医疗服务系统的管理数据库中识别出COPD患者。纳入所有在2000年9月1日至2001年8月31日期间被诊断为COPD且接受过至少3个月以下任一治疗的患者:氟替卡松/沙美特罗联合吸入器(FSI,N = 866)、任何与LABA联用的ICS(ICS/LABA,N = 525)、单用ICS(N = 742)、单用LABA(N = 531)或单用短效支气管扩张剂(SABD,N = 1832)。使用三种不同的分析方法进行分析,以校正可能影响结果的各种偏倚。在基本的Cox比例风险模型中,校正年龄、性别、合并症、哮喘状态和疾病严重程度的差异后,与SABD相比,使用FSI、ICS/LABA、单用ICS和单用LABA均具有显著的生存获益(风险比分别为0.61 [0.45 - 0.83]、0.59 [0.46 - 0.77]、0.76 [0.61 - 0.95]、0.75 [0.57 - 0.98])。倾向评分匹配以减少治疗组与SABD参照组之间的临床差异,结果非常相似。基于生存状态而非治疗情况的巢式病例对照分析继续显示,FSI、ICS/LABA和单用ICS具有显著的生存获益。使用FSI或其他ICS联合或不联合LABA治疗与COPD患者生存率提高相关。治疗获益具有可重复性,并且对于应用多种旨在校正混杂变量差异和指征性偏倚的不同分析技术具有稳健性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验